Company profile
COMPASS PATHWAYS PLC
NASDAQ:CMPSBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PSILOCYBIN | phase3 | — | 7 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05733546 | phase2 | active_not_recruiting | 2023-01-30 | 2025-09-01 | COMPASS Pathways | A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder |
| NCT05481736 | phase2 | completed | 2022-10-12 | 2024-11-18 | COMPASS Pathways | Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study |
| NCT05624268 | phase3 | completed | 2023-01-24 | 2025-05-28 | COMPASS Pathways | Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD |
| NCT05711940 | phase3 | active_not_recruiting | 2023-02-14 | 2025-11-13 | COMPASS Pathways | Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD |
| NCT07570654 | phase2_3 | recruiting | 2026-09-01 | 2028-11-01 | COMPASS Pathways | Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder |
FDA applications (0)
No records yet.